Kratium (Diazepam)

Diazepam binds to a specific site on the GABA‑A receptor complex, enhancing the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx into neurons, leading to reduced neuronal excitability and producing calming, anticonvulsant, muscle‑relaxant, and sedative effects.

The dosage of Kratium is individualized and determined by the prescriber based on the patient’s condition, age, weight, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should set the appropriate dose.

Diazepam crosses the placenta and is excreted in breast milk. Its safety in pregnancy and lactation has not been fully established, and it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the Kratium product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Diazepam has a relatively long half‑life and high lipid solubility, providing prolonged therapeutic effects compared with shorter‑acting agents like lorazepam or midazolam. This can be advantageous for certain indications but may also increase the risk of accumulation and prolonged sedation in some patients.

Kratium should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly sealed to maintain sterility.

Kratium is supplied as a sterile solution for intramuscular, intravenous, or rectal administration. The route, dose, and rate of injection are determined by the prescribing clinician and should follow aseptic technique and local clinical guidelines.

Serious risks include respiratory depression, severe hypotension, paradoxical agitation, dependence with long‑term use, and the potential for withdrawal seizures if the drug is stopped abruptly. Patients should be monitored closely, especially when initiating therapy or adjusting the dose.

Kratium is contraindicated in patients with known hypersensitivity to diazepam or other benzodiazepines, those with acute narrow‑angle glaucoma, and individuals with severe respiratory insufficiency. Caution is also advised for patients with a history of substance abuse or severe hepatic impairment.